Navigation Links
Intellectual Property Lawyer Available for Comment on Recent Supreme Court Ruling
Date:3/24/2012

BUFFALO, N.Y., March 23, 2012  /PRNewswire/ -- Jeremy P. Oczek, a registered patent attorney and Member in the Intellectual Property and Technology Group of Bond Schoeneck & King, is available to comment on the recent Supreme Court ruling that has significant implications for the medical and biotechnology industries.

In Mayo Collaborative Services v. Prometheus Labs, Inc., the Court unanimously ruled that a medicine dosing process that merely describes a "natural law" is not eligible for patent protection. Writing for the Court, Justice Stephen G. Breyer said Prometheus Laboratories' medical tests, designed to help doctors determine the most beneficial drug dosage by describing the correlation between metabolites in patients' blood and the likelihood that the dosage will be ineffective or harmful, were directed to laws of nature and therefore not eligible for patent protection. Justice Breyer cited Einstein's E=mc(2) formula and Newton's law of gravity as celebrated examples of natural laws that courts have long held are not patentable.

Mr. Oczek, a registered patent attorney in the Buffalo office of Bond, Schoeneck & King, PLLC, has litigated patent cases in federal courts throughout the United States. He has offered commentary on intellectual property issues for many national publications, including The National Law Journal, BNA's Patent, Trademark & Copyright Journal and Law360, and has published articles on intellectual property law in the Buffalo Law Journal, Sedona Conference Journal and Boston College Law Review.

Bond, Schoeneck & King, PLLC is a full-service law firm of more than 200 attorneys with offices in New York State, Kansas and Florida. For a complete list of practice areas and industries served, please visit www.bsk.com

To arrange a phone interview with Mr. Oczek, please contact Kim Parr, Director of Public Relations at Latorra, Paul & McCann at (315) 476-1646, ext. 225 or email kparr@lpm-adv.com

Links

Opinion by Justice Stephen G. Breyer:
http://www.supremecourt.gov/opinions/11pdf/10-1150.pdf

New York Times: Justices Back Mayo Clinic Argument on Patents:
http://www.nytimes.com/2012/03/21/business/justices-reject-patents-for-medical-tests-relying-on-drug-dosages.html?scp=1&sq=mayo%20v%20prometheus%20supreme%20court&st=cse

Wall Street Journal: Top Court's Patent Rejection Alarms the Biotech Industry:
http://online.wsj.com/article/SB10001424052702304724404577293390828369720.html?mod=WSJ_hp_LEFTWhatsNewsCollection

Jeremy P. Oczek:
http://www.bsk.com/attorneys/bio.cfm?ID=3009

Bond, Schoeneck & King:
http://www.bsk.com/

Contact:
Kim Parr
Latorra, Paul & McCann
(315) 476-1646, ext. 225
kparr@lpm-adv.com


'/>"/>
SOURCE Bond Schoeneck & King
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. PharmacoFore, Inc. Announces Appointment of Chief Medical Officer and Vice President of Intellectual Property
2. Ontario Institute for Cancer Research Announces Enhancements to its Intellectual Property Development and Commercialization Program
3. iPierian Expands Leadership Team With Experienced Business Development and Intellectual Property Executives
4. China YCT International Group, Inc. Announces That the State Intellectual Property Office of the Peoples Republic of China has Approved a Patent to its Operating Subsidiary, Shandong Spring Pharmaceutical Co. Ltd.
5. BIO Ventures for Global Health Chosen to Administer the GSK and Alnylam Intellectual Property Pool
6. Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property
7. Finn, Warnke & Gayton Announces A New Service For Biotechnology Firms - A Platform To Sell Intellectual Property
8. Veteran Intellectual Property Team Joins Brown Rudnick
9. EPIX Pharmaceuticals, Inc. Announces the PRX-00023 Therapeutics CNS Program in Phase 2b/3 Will Be Part of the Intellectual Property Offered for Sale at the September 30, 2009 Auction
10. Epix Pharmaceuticals, Inc. Announces the PRX-08066 Therapeutics Program in Phase 2 for Respiratory Indication Will Be Part of The Intellectual Property Offered for Sale at the September 30, 2009 Auction
11. Hill-Rom Announces Sale of Negative Pressure Wound Therapy Intellectual Property
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... ComplianceOnline, the leading governance, risk ... its 3rd Annual Medical Device Summit 2017 venue and speaker lineup. The Summit will ... in Boston, MA. , The Omni Parker House Hotel, which is located at 60 ...
(Date:3/29/2017)... , March 29, 2017  Halozyme Therapeutics, ... oncology and drug-delivery therapies, today announced that an ... and Drug Administration voted 11 to 0 that ... skin) injection was favorable for patients in the ... lymphoma and chronic lymphocytic leukemia. The FDA action ...
(Date:3/29/2017)... ... March 29, 2017 , ... ACEA Biosciences, a privately owned ... travel award to noteworthy scientists who will be presenting research using ACEA Biosciences’ ... of awards are being given to two postdoctoral fellows studying pathogen capture by ...
(Date:3/29/2017)... ... March 29, 2017 , ... Bactana Animal Health, a company developing natural products ... through enhancement of the gut microbiota, today announced the closing of its first round ... York-based Sustainable Income Capital Management, LLC and a number of private investors. The company ...
Breaking Biology Technology:
(Date:3/7/2017)... 2017 Brandwatch , the leading social intelligence company, ... Trust to uncover insights to support its reporting, help direct ... The UK,s leading youth charity will be using Brandwatch Analytics social ... a better understanding of the topics and issues that are a ... ...
(Date:3/2/2017)... YORK , March 2, 2017 Summary ... better understand Perrigo and its partnering interests and activities since ... ... Partnering Deals and Alliance since 2010 report provides an in-depth ... leading life sciences companies. On demand company reports ...
(Date:3/2/2017)... March 2, 2017 Australian stem cell and ... CYP), has signed an agreement with the Monash Lung ... Biomedicine Discovery Institute and Department of Pharmacology at Monash ... further preclinical study to support the use of Cymerus™ ... Asthma is a chronic, long term ...
Breaking Biology News(10 mins):